C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter C—Drugs: GeneralPart 211—Current Good Manufacturing Practice for Finished PharmaceuticalsSubpart A—General Provisions

21 C.F.R. § 211.1 (2026)

Scope

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1978–2026 8citing cases
At a glance

Courts have cited this section in 8 opinions since 1978, 2 of them in the last five years.

(a) The regulations in this part contain the minimum current good manufacturing practice for preparation of drug products (excluding positron emission tomography drugs and medical gases as defined in § 213.3(b)(12) of this chapter) for administration to humans or animals.

(b) The current good manufacturing practice regulations in this chapter as they pertain to drug products; in parts 600 through 680 of this chapter, as they pertain to drugs that are also biological products for human use; and in part 1271 of this chapter, as they are applicable to drugs that are also human cells, tissues, and cellular and tissue-based products (HCT/Ps) and that are drugs (subject to review under an application submitted under section 505 of the act or under a biological product license application under section 351 of the Public Health Service Act); supplement and do not supersede the regulations in this part unless the regulations explicitly provide otherwise. In the event of a conflict between applicable regulations in this part and in other parts of this chapter, or in parts 600 through 680 of this chapter, or in part 1271 of this chapter, the regulation specifically applicable to the drug product in question shall supersede the more general.

(c) Pending consideration of a proposed exemption, published in the Federal Register of September 29, 1978, the requirements in this part shall not be enforced for OTC drug products if the products and all their ingredients are ordinarily marketed and consumed as human foods, and which products may also fall within the legal definition of drugs by virtue of their intended use. Therefore, until further notice, regulations under parts 110 and 117 of this chapter, and where applicable, parts 113 through 129 of this chapter, shall be applied in determining whether these OTC drug products that are also foods are manufactured, processed, packed, or held under current good manufacturing practice.

[43 FR 45077, Sept. 29, 1978, as amended at 62 FR 66522, Dec. 19, 1997; 69 FR 29828, May 25, 2004; 74 FR 65431, Dec. 10, 2009; 80 FR 56168, Sept. 17, 2015; 89 FR 51769, June 18, 2024]
The 8 cases that cite 21 C.F.R. § 211.1 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENLivingston v. Wyeth, Inc., 520 F.3d 344 (4th Cir. 2008).
cites § 211.1 2×cited by 47 cases
Where it cites § 211.1
“" 21 C.F.R. § 211.1 . In addition to specific mandates, such as requiring workers to wear clean clothing during drug production, see id.”
The case’s holding
A whistleblower must demonstrate both a subjective belief and an objectively reasonable belief that the employer's conduct constitutes a violation of securities laws.
Later courts cite it for
“must show not only that he believed that the conduct constituted a violation, but also that a reasonable person in his position would have believed that the conduct constituted a violation.” · 3 citing courts
2
GREENSupernus Pharm., Inc. v. TWi Pharm., Inc., 265 F. Supp. 3d 490 (D.N.J. 2017).
cites § 211.1 1×cited by 4 cases
Where it cites § 211.1
“Because 21 C.F.R. § 211.1 (a) requires that experimental drugs pass FDA .”
cites § 211.1 1×cited by 16 cases
Where it cites § 211.1
“The evidence conclusively establishes that Consolidated, in the preparation and repacking of its dihycon and colchicine, did not conform to current good manufacturing practice as defined in 21 C.F.R. § 211.1 (a) which states that the “criteria in §§ 211.”
4
GREENMohr v. Targeted Genetics, Inc., 690 F. Supp. 2d 711 (C.D. Ill. 2010).
cites § 211.1 1×cited by 2 cases
Where it cites § 211.1
“, 21 C.F.R. § 211.1 (“regulations in this part contain the minimum *727 current good manufacturing practice for preparation of drug products for administration to humans and animals”).”
5
GREENUnited States v. Argent Chem. Labs., Inc., 93 F.3d 572 (9th Cir. 1996).
cites § 211.1 1×cited by 25 cases
Where it cites § 211.1
“72 ; production and process controls, 21 C.F.R. §§ 211.1 GO-211.115; packaging and labeling controls, 21 C.”
6
NO FLAGTorrent Pharma, Inc. v. Priority Healthcare Distrib., Inc., No. N18C-05-094 CEB, 2022 WL 3272421 (Del. Super. Ct. Aug. 11, 2022).
cites § 211.1 1×cited by 0 cases
Summary
No passage or summary on file for this case yet.
7
NO FLAGShareholder Rep. Servs., LLC v. Alexion Pharm., Inc., No. 2020-1069-MTZ (Del. Ch. May 27, 2026).
cites § 211.1 1×cited by 0 cases
Where it cites § 211.1
“130 (citing to Phase 1 Guidance); Phase 1 Guidance § III (“[I]f an investigational drug has already been manufactured by an IND sponsor for use during phase 2 or phase 3 clinical trials or has been lawfully marketed, manufacture of such a drug must comply (21 CFR 211.1) with 21…”
8
NO FLAGBoudreault v. Chesapeake Biological Labs., Inc., 19 Mass. L. Rptr. 484 (Mass. Super. Ct. 2005).
cites § 211.1 1×cited by 0 cases
Where it cites § 211.1
“While the plaintiff has not set out any policy in Massachusetts upon which to base his public policy exception, he points out that the FDA can dictate public policy, more specifically the policies *486 set forth in 21 C.F.R. §211.1 . Similarly to the plaintiff in Wright ,…”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
197820022026

One bar per year. Tallest: 1 case in 1978. 2026 is a partial year. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
4th Cir.19th Cir.1Del. Ch.1Del. Super. Ct.1C.D. Ill.1Mass. Super. Ct.1D.N.J.1S.D.N.Y.1
By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com